Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI – Get Rating) crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.95 and traded as high as $1.30. Spectrum Pharmaceuticals shares last traded at $1.30, with a volume of 6,803,425 shares changing hands.
Analysts Set New Price Targets
SPPI has been the topic of several research reports. Cantor Fitzgerald reiterated a “neutral” rating on shares of Spectrum Pharmaceuticals in a report on Wednesday, June 8th. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Spectrum Pharmaceuticals in a report on Friday, May 27th. JMP Securities restated a “buy” rating and issued a $4.00 target price on shares of Spectrum Pharmaceuticals in a report on Tuesday, June 7th. Finally, StockNews.com upgraded shares of Spectrum Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $6.00.
Spectrum Pharmaceuticals Stock Up 2.8 %
The stock’s 50-day moving average price is $1.04 and its two-hundred day moving average price is $0.95. The stock has a market capitalization of $243.67 million, a P/E ratio of -1.77 and a beta of 1.86. The company has a current ratio of 1.79, a quick ratio of 1.79 and a debt-to-equity ratio of 0.15.
Institutional Inflows and Outflows
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma.
- Get a free copy of the StockNews.com research report on Spectrum Pharmaceuticals (SPPI)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for Spectrum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.